<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554787</url>
  </required_header>
  <id_info>
    <org_study_id>DMR100-IRB-251</org_study_id>
    <nct_id>NCT01554787</nct_id>
  </id_info>
  <brief_title>Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <brief_summary>
    <textblock>
      The high levels of fatigue in stroke patients without neurological impairment suggest it has&#xD;
      a central origin rather than being the result of increased physical effort required after&#xD;
      stroke（Winward et al., 2009）. Fatigue is different from post-stroke depression and the more&#xD;
      serious stroke patients are more prone to fatigue（Windward et al., 2009）.&#xD;
&#xD;
      Fatigue is one of the symptoms of qi deficiency,and Astragalus membranaceus is the most&#xD;
      effective of all traditional Chinese medicine and can tonifying middle and tonify the&#xD;
      original qi. Therefore, the aim of this study was to investigate the efficacy of Astragalus&#xD;
      membranaceus on post-stroke fatigue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>2 year(all patients)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BFI-T score</measure>
    <time_frame>2 years(all patients)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36 score</measure>
    <time_frame>2 years(all patients)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fatigue</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Chinese Herb Astragalus membranaceus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chinese Herb Astragalus membranaceus</intervention_name>
    <description>Astragalus membranaceus(AM)at a rate of 2.8g three times per day</description>
    <arm_group_label>Chinese Herb Astragalus membranaceus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>at a rate of 2.8g three times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender: Male or female.&#xD;
&#xD;
          2. Age: between 40 and 80 years old.&#xD;
&#xD;
          3. Three months after stroke.&#xD;
&#xD;
          4. Hemorrhagic stroke or ischemic stroke.&#xD;
&#xD;
          5. Fatigue score from screen process ≧4.&#xD;
&#xD;
          6. Subject with comprehension or communication.&#xD;
&#xD;
          7. Volunteer signs the agreement to participate the study after whole study purpose and&#xD;
             procedures description in detail.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. People from mental illness can not to participate the evaluation.&#xD;
&#xD;
          2. Major diseases such as cancer、Chronic pulmonary obstructive disease(COPD)、 Heart&#xD;
             failure、Myocardial Infraction、Chronic renal failure or Liver cirrhosis.&#xD;
&#xD;
          3. Pregnant woman.&#xD;
&#xD;
          4. Breast-feeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung Hsiang Liu, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chung Hsiang Liu, MD.</last_name>
    <phone>886-4-22052121</phone>
    <phone_ext>7635</phone_ext>
    <email>greengen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung Hsiang Liu, MD.</last_name>
    </contact>
    <investigator>
      <last_name>Chung Hsiang Liu, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>After stroke with fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

